弥漫性大B细胞淋巴瘤(DLBCL,diffuse large B-cell lymphoma)中激活致癌B细胞受体(BCR)信号的病理性机制,在很大程度上都是未知的。近日,一篇发表在国际杂志Blood Cancer Discovery上题为“Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma”的研究报告中,来自芬兰赫尔辛基大学等机构的...
B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow, blood or other organs. B-cell lymphomas are composed of large B lymphoid cells whose nuclear...
弥漫性大B细胞淋巴瘤(DLBCL,diffuse large B-cell lymphoma)中激活致癌B细胞受体(BCR)信号的病理性机制,在很大程度上都是未知的。近日,一篇发表在国际杂志Blood Cancer Discovery上题为“Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma”的研究报告中,来自芬兰赫尔辛基大学等机构的...
到了现代,局限期DLBCL患者的治疗进一步发展,需要重新考虑RT的作用、全身治疗的最佳时长以及PET代谢影像学在反应适应性(response-adapted)治疗中的新作用。 《Blood Cancer Journal》近日发表了一篇综述,芝加哥大学的Alexandra E. Rojek和Sonali M. Smith共同撰文,重点关注局限期DLBCL的治疗和相关研究(表1)、该疾病的挑战...
Adam J. Olszewski, Habibe Kurt, Andrew M. Evens; Defining and treating high-grade B-cell lymphoma, NOS.Blood2022 Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted ...
近日,来自美国哈佛大学的Catherine J. Wu, Gad Getz和Marcela V. Maus研究组在Nature Medicine上发表题为Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma的文章,收集了来自32位进行阿基...
相关研究结果近期发表在Blood期刊上,论文标题为“Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001”。 美国西北大学费恩柏格医学院的Leo I. Gordon 医学博士说,“最重要的是,2020年以来的所有数据在2024年都保持不变。我们在任何地方都有...
If your doctor tells you that you have B-cell lymphoma, it means you have a cancer that forms in white blood cells called lymphocytes. There's a lot to take in at first, but your doctor can explain what you can do to treat the disease. Make sure you reach out to family and friends...
[7]Yabe et al. Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma Blood Cancer Journal (2020) 10:32 https://doi.org/10.1038/s41408-020-0301-x. [8]Chen W; Kesler MV; Karandikar NJ; Kroft SH; Flow cytometric...
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. A small minority of these can be cured wi